A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis

• Published in: Osteoarthritis and cartilage Vol. 29; no. 5; pp. 654 - 666
• Main Authors: Yazici, Y., McAlindon, T.E., Gibofsky, A., Lane, N.E., Lattermann, C., Skrepnik, N., Swearingen, C.J., Simsek, I., Ghandehari, H., DiFrancesco, A., Gibbs, J., Tambiah, J.R.S., Hochberg, M.C.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2021
• Subjects: Clinical trial; CLK2; DYRK1A; Knee pain; Patient-reported outcomes; Wnt pathway; Knee pain; DYRK1A; Clinical trial; Patient-reported outcomes; Wnt pathway; CLK2

Lorecivivint (LOR; SM04690), an investigational Wnt pathway modulator, previously demonstrated patient-reported and radiographic outcome improvements vs placebo in clinically relevant subjects with moderate to severe knee osteoarthritis (OA). This study's objective was to identify effective LOR...